COPD: antiplatelet therapy and all-cause mortality | COPD

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Antiplatelet therapy in chronic obstructive pulmonary disease (COPD) may significantly lower all-cause mortality.

 

Study design/methods

  • Literature search identified 5 studies including 11117 COPD patients (3069 with acute exacerbation; 33% with ischemic heart disease [IHD]) for systematic review and meta-analysis.

 

Key Results

  • Antiplatelet therapy was common (47%; 95%CI 46%-48%; range 26%-61%).
  • All-cause mortality was significantly lower in COPD patients receiving antiplatelet treatment (odds ratio [OR] 0.81; 0.75-0.88), both in outpatients and in those with acute exacerbation.
  • Antiplatelet therapy was effective independent of potential confounders including IHD, cardiovascular drugs and cardiovascular risk factors, based on meta-regression.

 

Limitations

  • Limitations include those inherent in the included studies.

 

Why this matters

  • Patients with chronic obstructive pulmonary disease (COPD) are at high cardiovascular risk due to chronic inflammation and heightened platelet activation; meta-analysis suggests significantly lower all-cause mortality with antiplatelet therapy.